Levofloxacin Kabi (Levofloxacin Hemihydrate)

Levofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for DNA replication and transcription. This inhibition prevents bacterial DNA from unwinding and replicating, leading to bacterial cell death and providing a bactericidal effect against a broad range of Gram‑negative and Gram‑positive organisms.

The dose of Levofloxacin Kabi is determined by the prescribing clinician based on the type and severity of the infection, the patient’s renal function, age, weight, and any concomitant medications. Only a qualified healthcare professional can set the appropriate dosing regimen for each individual case.

Levofloxacin is classified as pregnancy category unknown, and safety data are limited. It should be used during pregnancy or lactation only if the potential benefits justify the potential risks to the fetus or infant. Clinicians must evaluate each situation carefully before prescribing.

To order Levofloxacin Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Levofloxacin offers broad‑spectrum activity with once‑daily dosing for many indications, which can be an advantage over some older fluoroquinolones that require multiple daily doses. Compared with beta‑lactam antibiotics, levofloxacin provides coverage of atypical pathogens and may be used when resistance to beta‑lactams is a concern. Choice of therapy should be guided by local susceptibility patterns and patient‑specific factors.

Levofloxacin Kabi should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Maintaining the cold‑chain ensures the stability and potency of the injectable product.

Levofloxacin Kabi is administered intravenously as a sterile solution. The infusion is given by a healthcare professional, typically over a period of 30‑60 minutes, depending on the prescribed dose and clinical protocol. Intravenous administration allows rapid achievement of therapeutic plasma concentrations.

Serious risks include tendon rupture or tendinitis, especially in older adults; QT‑interval prolongation leading to potentially life‑threatening arrhythmias; severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome; Clostridioides difficile‑associated colitis; and central nervous system effects like seizures or psychosis. Patients should be monitored closely for these events.

Levofloxacin Kabi should be avoided in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with significant QT prolongation or uncontrolled cardiac arrhythmias, and patients with severe renal impairment unless dose adjustments are made. Clinical judgment is essential.